Abera Bioscience shifts financial reporting to IFRS from 2026 annual report

Bitget2026/10/06 11:46

Abera Bioscience will switch financial reporting to IFRS as it prepares for potential future capital-markets opportunities. Interim reports in 2026 will remain under Sweden’s K3 standard. The 2026 annual report will be prepared under IFRS. Quarterly reporting will move to IFRS from Q1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abera Bioscience AB published the original content used to generate this news brief via Cision (Ref. ID: 202610060746BITN____UKPR__SV_20261006-BIT-9716-0) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.